| Name | Title | Contact Details |
|---|
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts with cutting through complexity and focusing on the human side of healthcare. By continuously advancing and integrating our solutions, we enable clinicians to be vitally connected to their patients by delivering timely data and actionable insights. That means more accurate diagnoses, earlier intervention and faster recovery times. Our innovations put more heart in healthcare. Through more intelligent—and more connected—solutions, we help simplify routine workflows and communication, enabling care teams to focus on their passion—helping patients get better sooner. And we continuously raise the bar on quality and safety, building upon our legacy of trust with providers around the world. As healthcare continues to evolve, we`re here to support the people at the heart of it. Hillrom. Advancing Connected Care™.
Medgear Medical Uniforms is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Young Dental is a Earth City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AIC-Isreal is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.